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Abstract 
Background: Despite its beneficial role on insulin resistance and atherosclerosis, adiponectin has been repeatedly 
reported as an independent positive predictor of cardiovascular mortality.
Methods: A Mendelian randomization approach was used, in order to evaluate whether such counterintuitive 
association recognizes a cause-effect relationship. To this purpose, single nucleotide polymorphism rs822354 in the 
ADIPOQ locus which has been previously associated with serum adiponectin at genome-wide level, was used as an 
instrument variable. Our investigation was carried out in the Gargano Heart Study-prospective design, comprising 
356 patients with type 2 diabetes, in whom both total and high molecular weight (HMW) adiponectin were measured 
and cardiovascular mortality was recorded (mean follow-up = 5.4 ± 2.5 years; 58 events/1922 person-year).
Results: The A allele of rs822354 was associated with both total and HMW adiponectin [β (SE) = 0.10 (0.042), 
p = 0.014 and 0.17 (0.06), p = 0.003; respectively]. In a Poisson model comprising age, sex, smoking habits, BMI, 
HbA1c, total cholesterol, HDL-cholesterol, triglycerides, insulin therapy and hypertension, both rs822354 (IRR = 1.94, 
95 % CI 1.23–3.07; p = 0.005), as well as the genetic equivalent of total adiponectin change (IRR = 1.07, 95 % CI 
1.02–1.12; p = 0.003) were significantly associated with cardiovascular mortality. The observed genetic effect was 
significantly greater than that exerted by the genetic equivalent change of serum adiponectin (p for IRR heterogene-
ity = 0.012). In the above-mentioned adjusted model, very similar results were obtained when HMW, rather than total, 
adiponectin was used as the exposure variable of interest.
Conclusions: Our data suggest that the paradoxical association between high serum adiponectin levels and 
increased cardiovascular mortality rate is based on a cause-effect relationship, thus pointing to an unexpected delete-
rious role of adiponectin action/metabolism on atherosclerotic processes.
Keywords: Adiponectin, ADIPOQ, Mortality, Mendelian randomization, Type 2 diabetes
© 2016 Ortega Moreno et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Despite insulin-sensitizing, anti-inflammatory and 
endothelial protective effects [1–4], adiponectin is an 
independent positive predictor of cardiovascular (CV) 
mortality in the general population [5] as well as several 
clinical sets [6–15] including type 2 diabetes (T2D) [16]. 
Because of such paradox, it is logical to suspect that high 
adiponectin rather than being a true risk factor is simply 
a marker of other metabolic disturbances, which, in fact, 
are able to causally shape the risk of CV mortality.
Genetic variants, which are robustly associated with 
a given modifiable variable, are strong and easy-to-use 
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tools for assessing if causality underlines the association 
between that variable, used as an exposure, and outcomes 
of interest [17–19]. In our case, if genetic variants, firmly 
associated with circulating adiponectin levels, prove to 
be also associated with CV death, a strong case is made 
in favor of a causal role of adiponectin on CV mortality.
We and others have recently reported that single nucle-
otide polymorphism (SNP) rs822354, located in the locus 
of ADIPOQ, the gene which encodes for adiponectin 
[20], is associated with serum adiponectin at genome-
wide level of statistical significance [21, 22].
Based on this background, we used rs822354 as an 
instrumental variable to investigate the causal nature of 
the counterintuitive independent association between 
adiponectin and CV mortality we have previously 
reported in patients with T2D [16].
Methods
Study population
Gargano Heart Study (GHS)‑prospective design
This study comprises 368 patients with T2D (ADA 2003 
criteria) and coronary artery disease (CAD) who were 
consecutively recruited at the Endocrine Unit of IRCCS 
“Casa Sollievo della Sofferenza” in San Giovanni Rotondo 
(Gargano, Center East Coast of Italy) from 2001 to 2008, 
as recently described [16, 23, 24]. All patients had either 
a stenosis >50 % in at least one coronary major vessel at 
coronary angiography or a previous myocardial infarc-
tion (MI). Follow-up information on outcomes was col-
lected yearly from 2002 to 2011. The only exclusion 
criterion was the presence of poor life expectancy for 
non diabetes-related diseases. The end-point was CV 
mortality. Confirmation of the event was obtained from 
death certificates (i.e. according to the international clas-
sification of diseases’ codes: 428.1—ninth edition- and 
I21.0–21.9, I25.9, I46.9–50.9, I63.0, I63.9, I70.2-tenth 
edition). Clinical data at baseline were obtained from a 
standardized interview and examination. Smoking habits 
and history of hypertension, dyslipidemia and MI as well 
as glucose-lowering treatment were also recorded at time 
of examination. Data regarding medications were con-
firmed by review of medical records.
Serum total and high-molecular weight (HMW) adi-
ponectin and genotyping of SNP rs822354 were assessed 
in 356 (96.7 %) participants.
The study was approved by the Institutional Ethic 
Committee IRCCS “Casa Sollievo della Sofferenza”, San 
Giovanni Rotondo.
Measurement of circulating total adiponectin levels
Serum total and HMW adiponectin concentrations 
were measured by ELISA (Alpco, Salem, NH) as previ-
ously described [25, 26]. The intra-assay coefficients of 
variation were 5.4 and 4.9, and 5.0 and 4.8 % for total adi-
ponectin and HMW adiponectin, respectively [16].
Genotyping
SNP rs822354 was genotyped by Taqman SNP allelic dis-
crimination technique by means of an ABI 7000 (Applied 
Biosystems, Foster City, CA). Call rate and concordance 
rate were ≥96 and >99  %, respectively. The SNP was in 
Hardy–Weinberg equilibrium (HWE) (p > 0.05).
Statistical methods
Patients’ baseline characteristics were reported as 
mean ±  standard deviation (SD) and percentages for con-
tinuous and categorical variables, respectively. Deviation 
from HWE of the rs822354 was investigated by exact χ2 test.
Univariable linear regression analysis was performed to 
model the effect of the rs822354 polymorphism (assum-
ing an additive genetic model of inheritance) on adi-
ponectin levels (expressed in terms of log transformed 
because of its non-normal distribution) and results were 
reported as regression coefficient β (standard error, SE).
The time variable was defined as the time between the 
baseline examination and date of the event (CV mortal-
ity), or, for subjects who did not experience the event, the 
date of the last available clinical follow-up. Incidence rate 
(IR) for CV mortality was expressed as the number of 
events per total number of 100 person-years (py).
To estimate the causal effect of adiponectin levels on 
CV mortality, we performed mediation analyses using 
SNP rs822354 as instrumental variable.
Poisson regression models were performed to assess 
the association between rs822354 (per one risk allele 
increase), adiponectin values and the event occurrence. 
Risks were reported as incidence rate ratio (IRR) along 
with 95 % confidence interval (95 % CI).
Such models were used to estimate the effect size per 
minor allele of rs822354 polymorphism on adiponectin 
levels (β1) and on CV mortality (β2), and the effect size of 
adiponectin levels (rescaled by β1) on CV mortality (β3). 
Mendelian randomization holds if β2 and β3 are not sta-
tistically different. To test such difference, we introduced 
a bivariate generalized linear model with Poisson distri-
bution, which allowed to simultaneously estimate both 
adjusted models (CV mortality vs. SNP rs822354 and CV 
mortality vs. adiponectin levels), using an appropriate 
statistical contrast.
Our sample size of 356 patients achieved a statisti-
cal power of 80  % (two-sided type I error rate  =  0.05) 
to detect an allelic IRR on CV mortality at least equal to 
1.70, given its annual IR of 3 % and a risk allele frequency 
of 0.37 we observed in our sample.
Two-sided p values <0.05 were considered for statisti-
cal significant.
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All analyses were performed using SPSS version 15.0 
(Chicago, IL) and SAS release 9.3 (SAS Institute, Cary, 
NC).
Results
Clinical features of patients from GHS are summarized in 
Table 1. During follow-up (5.4 ± 2.5 years), 58 CV deaths 
occurred, corresponding to an overall annual IR of 3.0 % 
(58 events/1922 py).
In these patients, the A allele of rs822354 was signifi-
cantly associated with total adiponectin (β (SE)  =  0.10 
(0.042); p =  0.014). In addition, in a model comprising 
several variables relevant to the risk of death, includ-
ing age, sex, smoking habits, BMI, HbA1c, total choles-
terol, HDL-cholesterol, triglycerides, insulin therapy 
and hypertension, both the same allele at rs822354 
(IRR  =  1.94, 95  % CI 1.23–3.07; p  =  0.005), as well 
as the genetic equivalent of total adiponectin change 
(IRR  =  1.07, 95  % CI 1.02–1.12; p  =  0.003), were sig-
nificantly associated with CV mortality. Of note, the 
observed genetic effect was significantly greater than that 
exerted by the genetic equivalent change of serum adi-
ponectin (i.e. change per one rs822354 allele) (p for IRR 
heterogeneity = 0.012) (Fig. 1a).
Similarly, rs822354 was associated with HMW adi-
ponectin (β (SE) = 0.17 (0.06); p = 0.003), whose genetic 
equivalent change was, in turn, associated with CV mor-
tality (adjusted IRR = 1.12, 95 % CI 1.04–1.21; p = 0.003). 
Also in this case, the association of CV mortality with 
either rs822354 or the genetic equivalent change of 
serum HMW adiponectin was significantly different (p 
for IRR heterogeneity = 0.021) (Fig. 1b).
Discussion
Many cardiovascular risk factors recognize a genetic 
background [27–29]. Beside unraveling new pathogenic 
pathways, such genetic markers may be used as a tool for 
addressing the intrinsic nature underlying the relation-
ship between metabolic variables and a given outcome of 
interest, an approach known as Mendelian randomiza-
tion [30, 31].
Our data clearly show that the A allele of SNP rs822354 
(in the ADIPOQ locus, which encodes for adiponectin 
[20]), is associated not only with high serum adiponectin 
levels (both total and HMW isoform), but also and most 
importantly with high CV mortality rate.
This finding is perfectly in line with a previous study 
showing that the G allele of SNP rs4783244 (in CDH13, 
encoding for the HMW adiponectin receptor T-cadherin 
[32]) is associated with both high HMW adiponectin lev-
els [33–35] and increased mortality rate [35].
Although the exact mechanism through which SNP 
rs4783244 (or others in linkage disequilibrium, LD, with 
Table 1 Baseline clinical characteristics of  participants 
from GHS (N = 356)
Continuous variables were reported as mean ± SD whereas categorical variables 
as total frequency and percentages
GHS Gargano heart study, BMI body mass index, HbA1c glycated haemoglobin 
A1c HDL-cholesterol high density lipoprotein-cholesterol, HMW-adiponectin high 
molecular weight-adiponectin
Males (%) 67.4
Age (years) 64.5 ± 8.2
Smokers (%) 63 (17.7)
BMI (kg/m2) 30.2 ± 4.8
HbA1C (%) 8.6 ± 1.9
Total cholesterol (mg/dl) 176.0 ± 45.8
HDL-cholesterol (mg/dl) 43.6 ± 14.6
Tryglicerides (mg/dl) 152.3 ± 91.8
Insulin w/wh oral agents (%) 192 (54.0)
Hypertension (%) 302 (84.8)
HMW-adiponectin (µg/ml) 3.1 ± 2.5
Total adiponectin (µg/ml) 4.9 ± 2.9
SNP rs822354
β3: IRR (95%CI) per 0.10 adiponecn change = 1.07 (1.02-1.12)
p = 0.012
Total adiponecn CV mortality
SNP rs822354
β3: IRR (95%CI) per 0.17 adiponecn change = 1.12 (1.04-1.21)
p = 0.021
HMW adiponecn CV mortality
a
b
Fig. 1 a Instrumental variable analysis for total adiponectin circulat-
ing levels. β1 effect size of association between each minor allele 
of rs822354 and total adiponectin levels; β2 effect size of associa-
tion between each minor allele of SNP rs822354 and CV mortality; 
β3 effect size of association between change of total adiponectin 
levels attributable to the effect of rs822354 (i.e. genetic equivalent 
of total adiponectin change) and CV mortality. b Instrumental vari-
able analysis for HMW adiponectin circulating levels. β1 effect size 
of association between each minor allele of rs822354 and HMW 
adiponectin levels; β2 effect size of association between each minor 
allele of SNP rs822354 and CV mortality; β3 effect size of association 
between change of HMW adiponectin levels attributable to the effect 
of rs822354 (i.e. genetic equivalent of HMW adiponectin change) and 
CV mortality
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it) affects serum adiponectin is a matter of debate [33, 
34], previous [35] and our present findings strongly sug-
gest that the paradoxical association between increased 
mortality risk and high serum adiponectin, rather than 
recognizing the latter as only a marker of yet unknown 
biologically-unlinked abnormalities, is explained by a 
causal, deleterious effect of adiponectin action and/or 
metabolism [36, 37] on mortality rate.
Given the well-known beneficial effect of adiponectin 
on several metabolic and vascular phenotypes [4, 38–40], 
the intrinsic biological nature underlying such deleteri-
ous effect(s) is difficult to understand or even only to 
speculate; otherwise, we would not be talking of “para-
doxical effect/association”. Having acknowledge this, 
some deleterious actions of adiponectin on processes 
possibly involved in atherogenesis, including stimulatory 
effect on secretion of pro-atherogenic cytokines [41–43] 
and angiogenesis [42, 44], have been recently reported 
in specific cell types. Whether such effects are observ-
able also in human tissues involved in atherogenesis and 
whether they may play a role in increasing atherosclerotic 
processes is a possibility that deserves further, specifically 
designed studies, to be addressed. As a matter of fact, the 
available literature on the association with human traits 
does not unequivocally point to adiponectin as a meta-
bolic and vascular protecting hormone. In fact, while 
low adiponectin has been associated with obesity, meta-
bolic syndrome [39], some macro- and micro-vascular 
damages [38, 40] and T2D [39], so to make reasonable 
hypothesize that drugs activating adiponectin signaling 
pathways improve all the above mentioned metabolic and 
vascular disturbances [4], on the other hand, adiponec-
tin levels are positively associated with subclinical ath-
erosclerosis in patients with type 1 diabetes [45] and with 
all-cause mortality in patients with T2D [46, 47].
An additional, unexpected, finding of our study is that 
the association between SNP rs822354 and CV mortal-
ity is stronger than that expected if it would be entirely 
mediated by serum adiponectin changes. Such discrep-
ancy might be due to the difference between a totally 
stable genetic effect, operating since birth on one hand 
and, conversely the role exerted by serum adiponec-
tin, whose levels are quite variable [48, 49], especially in 
heavily treated patients as are those with T2D [50, 51], 
and whose effect has been evaluated only for a few years. 
As an alternative explanation, we cannot exclude that, 
beside the role on serum adiponectin, rs822354 exerts 
additional, distinct (i.e. pleiotropic) effects through other 
risk factors, which either we cannot account for or are 
still unknown. At this regard, it is of note that although 
neither rs822354, nor other SNPs in high LD with it, 
are associated with CV traits in humans [52, 53], it is 
located in the 3q27.3 region close to KNG1, a potential 
contributor in shaping CV risk [54]. In fact, KNG1 
encodes for high molecular weight kininogen, the precur-
sor of bradykinin and kallidin, belonging to the pathway 
activating coagulation factors XI and XII [55] and inter-
related with the renin–angiotensin–aldosterone system 
[56].
We like to acknowledge some limitations of our study. 
Firstly, the sample we analyzed comprises only 356 indi-
viduals, so that the strength of the novel association we 
here report (i.e. between rs822354 and CV mortality) 
does not reach genome-wide level of statistical signifi-
cance. In addition, we lack a second, independent sample 
on which to replicate our finding. In all, although we can-
not exclude the possibility of a false positive result, our 
study plays the important role of hypothesis generating, 
thus representing a solid background on which further 
similar studies can be based on.
Conversely, strengths of our study are the deep clinical 
phenotyping and the genetic and environmental homo-
geneity of our sample recruited in a well-defined geo-
graphical region. In addition, also the determination of 
both total and HMW adiponectin, which allowed us to 
confirm our finding also with the biological active iso-
form of adiponectin [57], reinforces our study.
Finally, the observation that among community-dwell-
ing Japanese individuals [35], a genetic marker of adi-
ponectin levels is associated with all-cause mortality, 
suggests that our present finding is generalizable across 
different ethnicities and is not restricted to CV mortality 
in the specific subset of patients with T2D.
Conclusions
In conclusion, our present and previous [35] data suggest 
that adiponectin action/metabolism paradoxically causes 
increased CV mortality risk. Further studies are needed 
before this unexpected finding may be considered as 
established.
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